The European Medicines Agency's committee for medicinal products for human use ( CHMP) has turned down AB Science's application to market pancreatic cancer drug Masiviera (masitinib) in Europe.
This marks the second CHMP rejection for an AB Science cancer drug with the active ingredient masitinib in recent months. In its November meeting the CHMP returned a negative...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?